GSK Archives

News and Trends 3 Sep 2015

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Adaptimmune has had exciting results regarding the ongoing battle with Synovial Sarcoma. GSK looks to further invest in the expansion of the clinical trial to include two further cohorts. Adaptimmune, with a research base in Oxford (UK) and clinical base in Philadelphia (US), has overcome a milestone in their first cohort for clinical stage I/II T-cell therapy. They […]

September 3, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Aug 2015

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was formed from the 70-year old duck breeder Group Grimaud. It entered the biotech scene in 2000 as Vivalis and today is on Euronext-Paris and the Vienna stock exchange, has a market cap of about €275M […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 24 Aug 2015

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

Is this Novartis‘ next blockbuster? The Swiss company has acquired GlaxoSmithKline‘s (GSK) immunosuppressive antibody Ofatumumab for up to $1Bn. The new drug allows Novartis to enter the multiple sclerosis market for the third time. Earlier this year, Novartis purchased GSK’s oncology portfolio for $16 billion (€14Bn), including the fully human monoclonal anitbody Ofatumumab, which is […]

August 24, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Aug 2015

A 100% Successful Ebola Vaccine Available in a Record Time

It’s a really good news in the fight against Ebola. A vaccine has shown 100% success to prevent the disease during the outbreak in Guinea! The vaccine, which has been tested in a record time, can be the key to end the west African epidemics. In an interim analysis published by The Lancet, the new vaccine has […]

August 4, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

The future Francis Crick Institute has established its first industrial collaboration, even before opening its doors. And the lucky nominee couldn’t have been any other than GlaxoSmithKline, the UK’s largest pharmaceutical company. The partners are seeking to better understand human diseases, hoping that the research will lead to innovative drugs against a broad range of disorders. The […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 May 2015

Axovant banks on GSK’s scrapped project

Last December, Axovant acquired for €4.5M ($5 million) the drug candidate SB742457 from GlaxoSmithKline. Four months later, the company announced its initial public offering to raise up to €154M ($173 million). Why is this newly funded company betting on the leftovers of the Big Pharma? The drug candidate SB742457 is a selective 5-HT6 receptor antagonist, developed as an oral […]

May 13, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 5 Mar 2015

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small […]

March 5, 2015 - 5 minutesmins - By Cédric Brock

News and Trends 14 Feb 2015

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company. GlycoVaxyn’s innovative biological conjugation platform originates enables the development of […]

February 14, 2015 - 2 minutesmins - By Lourdes Riquelme

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 19 Aug 2014

GSK abandon its joint drug project with Galapagos

According to Reuters, Galapagos, a Belgian biotech group announced that GlaxoSmithKline has stopped a joint drug development project over concerns about adverse effects. In June 2006, Galapagos signed a broad alliance with GSK to discover and develop breakthrough medicines. This multi-target, multi-year alliance runs from target discovery through to delivery of a clinical Proof of Concept. […]

August 19, 2014 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GSK

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

A 100% Successful Ebola Vaccine Available in a Record Time

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

Axovant banks on GSK’s scrapped project

GSK sparks off the Gene Therapy resurgence

Novartis announces completion of transactions with GSK

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

Novartis steps down completely from Vaccines’ Business

GSK abandon its joint drug project with Galapagos

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!